Addex Pharma S.A. / “Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment

Date Published March 17, 2026

Midwest Neuroscience, Neurology and Cognitive Disorders
No summary available

COM Affiliation

Funding Type

Corporate Grant (for-profit and non-profit)

Update This Listing

Help us provide the most up-to-date information about this project.

Contact Us
Questions?

For questions about these research projects please email us.

Contact Us